Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
Dietary supplement use throughout the colorectal cancer disease trajectory: a prospective cohort study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zwart Nienke R K, Verstraete Femke Fleur, Wesselink Evertine, Winkels Renate M, van Duijnhoven Fränzel J B, de Wilt Johannes H W, Kampman Ellen, Kok Dieuwertje E
Аннотация
PURPOSE: Dietary supplement use is common in the general population, but literature addressing supplement use throughout the disease trajectory in colorectal cancer (CRC) survivors is limited.
METHODS: Data from the COLON study, a prospective cohort among participants diagnosed with stage I-IV CRC, were used. Participants were asked to fill out a dietary supplement questionnaire at diagnosis (n = 1934), 6 months post-diagnosis (n = 1769), 2 years post-diagnosis (n = 1533), and 5 years post-diagnosis (n = 1198) containing questions on type, brand, frequency, and doses of supplements. Participants were considered regular supplement users if they used ≥ 1 supplement(s) at least once a week.
RESULTS: Supplement use was reported in 43% of participants at diagnosis, 42% at 6 months post-diagnosis, 45% at 2 years post-diagnosis, and 53% at 5 years post-diagnosis. Multivitamins, vitamin D, and vitamin C were most often reported. Almost half of the participants (48%) with data across all timepoints (n = 1146) changed their dietary supplement use at least once during the 5 years post-diagnosis, whereas 26% were consistent users and 26% consistent non-users. The tolerable upper intake level was exceeded for 1-2% of vitamin D users, 7-13% of vitamin B6 users, 4-5% of folic acid users, 14-32% of magnesium users, and 6-23% of iron users. Across all timepoints, female and higher educated participants were more likely to use supplements. Participants diagnosed with stage III/IV CRC (versus I/II) and those receiving adjuvant treatment (versus not receiving) were less likely to use supplements at 6 months and 2 years post-diagnosis.
CONCLUSION: Dietary supplement use is common among CRC survivors. Given the regular use of supplements, the potential impact of (high-dose) supplement use on clinical outcomes warrants further investigation.
METHODS: Data from the COLON study, a prospective cohort among participants diagnosed with stage I-IV CRC, were used. Participants were asked to fill out a dietary supplement questionnaire at diagnosis (n = 1934), 6 months post-diagnosis (n = 1769), 2 years post-diagnosis (n = 1533), and 5 years post-diagnosis (n = 1198) containing questions on type, brand, frequency, and doses of supplements. Participants were considered regular supplement users if they used ≥ 1 supplement(s) at least once a week.
RESULTS: Supplement use was reported in 43% of participants at diagnosis, 42% at 6 months post-diagnosis, 45% at 2 years post-diagnosis, and 53% at 5 years post-diagnosis. Multivitamins, vitamin D, and vitamin C were most often reported. Almost half of the participants (48%) with data across all timepoints (n = 1146) changed their dietary supplement use at least once during the 5 years post-diagnosis, whereas 26% were consistent users and 26% consistent non-users. The tolerable upper intake level was exceeded for 1-2% of vitamin D users, 7-13% of vitamin B6 users, 4-5% of folic acid users, 14-32% of magnesium users, and 6-23% of iron users. Across all timepoints, female and higher educated participants were more likely to use supplements. Participants diagnosed with stage III/IV CRC (versus I/II) and those receiving adjuvant treatment (versus not receiving) were less likely to use supplements at 6 months and 2 years post-diagnosis.
CONCLUSION: Dietary supplement use is common among CRC survivors. Given the regular use of supplements, the potential impact of (high-dose) supplement use on clinical outcomes warrants further investigation.